Chronic Obstructive Pulmonary Disease

Respiratory
81
Pipeline Programs
30
Companies
50
Clinical Trials
9
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
14
2
30
0
12
23
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
4100%
+ 99 programs with unclassified modality

On Market (9)

Approved therapies currently available

U
ACCUNEBApproved
albuterol sulfate
Unknown Company
inhalation2001
U
ALBUTEROL SULFATEApproved
albuterol sulfate
Unknown Company
inhalation2007
Regeneron
DUPIXENTApproved
dupilumab
Regeneron
Interleukin-4 Receptor alpha Antagonist [EPC]injection2017
Verona Pharma
OHTUVAYREApproved
ensifentrine
Verona Pharma
Phosphodiesterase 3 Inhibitor [EPC]inhalation2024
Teva
PROAIR DIGIHALERApproved
albuterol sulfate
Teva
inhalation2015
Teva
PROAIR HFAApproved
albuterol sulfate
Teva
inhalation2004
Teva
PROAIR RESPICLICKApproved
albuterol sulfate
Teva
inhalation2015
U
PROVENTIL-HFAApproved
albuterol sulfate
Unknown Company
inhalation1996
U
VOLMAXApproved
albuterol sulfate
Unknown Company
oral1992

Competitive Landscape

29 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
26 programs
5
2
1
Symbicort® forte Turbohaler®Phase 41 trial
Budesonide/formoterolPhase 35 trials
Treatment A : Budesonide, Glycopyrronium, and Formoterol FumaratePhase 31 trial
AZD1236Phase 22 trials
AZD2423Phase 22 trials
+21 more programs
Active Trials
NCT03425760Completed3,254Est. Mar 2017
NCT02552160Completed3,732Est. Dec 2017
NCT01285167Completed3,645Est. Feb 2012
+41 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
13 programs
1
8
Olodaterol-TiotropiumPhase 41 trial
Stiolto RespimatPhase 41 trial
TiotropiumPhase 41 trial
TiotropiumPhase 41 trial
TiotropiumPhase 41 trial
+8 more programs
Active Trials
NCT04360226Completed400Est. Jan 2024
NCT02119494Completed3,504Est. Dec 2015
NCT05295355Unknown72Est. Mar 2025
+10 more trials
Verona Pharma
Verona PharmaUK - London
8 programs
5
2
1
EnsifentrinePhase 31 trial
EnsifentrinePhase 31 trial
Ensifentrine 3 mgPhase 21 trial
Ensifentrine 3 mgPhase 21 trial
FormoterolPhase 21 trial
+3 more programs
Active Trials
NCT03799354RecruitingEst. Jul 2026
NCT07132983Completed33Est. Nov 2025
NCT07016412Recruiting480Est. Apr 2026
+5 more trials
Regeneron
RegeneronTARRYTOWN, NY
7 programs
1
1
4
1
DupilumabPhase 4Monoclonal Antibody
Dupilumab SAR231893Phase 3
Dupilumab SAR231893Phase 3
ItepekimabPhase 3Monoclonal Antibody
Itepekimab SAR440340Phase 3
+2 more programs
Takeda
TakedaTOKYO, Japan
4 programs
2
2
ARALAST NPPhase 42 trials
Ramelteon and PlaceboPhase 41 trial
Ramelteon and PlaceboPhase 21 trial
RoflumilastPhase 22 trials
Active Trials
NCT00672802Completed26Est. Mar 2004
NCT01701934Terminated14Est. Dec 2014
NCT00613587Completed15Est. Jan 2010
+3 more trials
Novartis
NovartisBASEL, Switzerland
3 programs
1
1
1
QVA149Phase 41 trial
IndacaterolPhase 31 trial
QAK423APhase 11 trial
Active Trials
NCT01197287Completed76
NCT01068600Completed318
NCT02125734Completed88Est. Jan 2015
Teva
TevaIsrael - Petach Tikva
3 programs
1
1
1
1
Albuterol sulfatePhase 31 trial
Tiotropium HFA BAI 5 mcgPhase 21 trial
TV48108Phase 11 trial
Active Trials
NCT02315144Terminated61Est. Aug 2015
NCT02203474Withdrawn0Est. Aug 2014
NCT03256695Completed405Est. Apr 2018
E
EisaiChina - Liaoning
1 program
1
lysozyme 90 mgPhase 41 trial
Active Trials
NCT01715493Completed48Est. Jan 2014
CT
10 programs
5
4
1
TQC3721 Suspension for inhalationPhase 31 trial
RoflumilastPhase 21 trial
TQC2731 injectionPhase 21 trial
TQC2938 injectionPhase 21 trial
TQC3721 suspension for inhalationPhase 21 trial
+5 more programs
Active Trials
NCT07267130RecruitingEst. Dec 2026
NCT05051930UnknownEst. Dec 2022
NCT06408285CompletedEst. Aug 2024
+7 more trials
Sanofi
SanofiPARIS, France
4 programs
2
1
Itepekimab SAR440340Phase 32 trials
Itepekimab SAR440340Phase 21 trial
SAR440340Phase 21 trial
Blood glucose monitoringN/A1 trial
Active Trials
NCT00467636Terminated51Est. May 2009
NCT05326412Completed49Est. Jul 2025
NCT03546907Completed343Est. Feb 2020
+2 more trials
CSL Behring
CSL BehringIL - Bradley
2 programs
1
Intravenous immunoglobulinPhase 21 trial
Pulmonary rehabilitationN/A1 trial
Active Trials
NCT02915614Unknown40Est. Jan 2024
NCT02690038Completed48Est. Nov 2019
Amgen
AmgenTHOUSAND OAKS, CA
2 programs
1
1
MP-376Phase 22 trials
MP-376Phase 11 trial
Active Trials
NCT00752414Completed21Est. Oct 2008
NCT00840333Completed27Est. Dec 2009
NCT00739648Completed322Est. Apr 2010
VP
2 programs
2
IvacaftorPhase 21 trial
Ivacaftor 150 MGPhase 21 trial
Active Trials
NCT04066751Withdrawn0Est. Oct 2024
NCT03085485Completed40Est. Sep 2022
Genentech
GenentechCA - Oceanside
1 program
1
AstegolimabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT05037929Completed1,334Est. Jul 2025
Mereo BioPharma
Mereo BioPharmaUK - London
1 program
1
BCT197Phase 2
Design Therapeutics
1 program
1
IMD-1041Phase 21 trial
Active Trials
NCT00883584UnknownEst. May 2009
Grifols
GrifolsNEW YORK, NY
1 program
1
Intravenous immunoglobulinPhase 2
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
Open-LabelPhase 21 trial
Active Trials
NCT00457951Terminated158Est. Oct 2009
Upstream Bio
Upstream BioWALTHAM, MA
1 program
1
VerekitugPhase 21 trial
Active Trials
NCT06981078RecruitingEst. Jul 2028
Pierre Fabre
Pierre FabreFrance - Aignan
1 program
1
BronchodilatatorPhase 1/21 trial
Active Trials
NCT01348555Completed108Est. Jul 2012
Alkermes
AlkermesDUBLIN 4, Ireland
1 program
1
trospium chloride inhalation powderPhase 1/21 trial
Active Trials
NCT00465959CompletedEst. Jun 2007
MediciNova
MediciNovaLA JOLLA, CA
2 programs
2
MN-221Phase 11 trial
MN-221Phase 11 trial
Active Trials
NCT01551316Completed19Est. May 2012
NCT01013142Completed48Est. Mar 2010
Pfizer
PfizerNEW YORK, NY
1 program
1
PF03635659Phase 11 trial
Active Trials
NCT00864786Completed50Est. Mar 2009
Zai Lab
Zai LabCA - South SF
1 program
1
ZL-2102Phase 11 trial
Active Trials
NCT02397005Unknown120Est. Aug 2019
Providence Therapeutics
2 programs
ACCEPT Decision InterventionN/A1 trial
Chronic Obstructive Pulmonary Disease Biomarker StudyN/A1 trial
Active Trials
NCT05309356UnknownEst. Jul 2025
NCT02050022UnknownEst. Dec 2021
Olympus
OlympusPA - Center Valley
1 program
IBV ValveN/A1 trial
Active Trials
NCT00880724Completed100Est. Jun 2010
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Integrated Disease ManagementN/A1 trial
Active Trials
NCT06456749Not Yet Recruiting4,000Est. Mar 2026
Beacon Therapeutics
Beacon TherapeuticsMA - Cambridge
1 program
ResWaveN/A1 trial
Active Trials
NCT06432920CompletedEst. Jan 2024
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
exposure to respirable silica dustN/A1 trial
Active Trials
NCT02220387CompletedEst. Sep 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AstraZenecaFormoterol
AstraZenecaFormoterol
TakedaARALAST NP
Boehringer IngelheimOlodaterol-Tiotropium
AstraZenecaFormoterol
AstraZenecaFormoterol
Boehringer IngelheimTiotropium & olodaterol
Boehringer IngelheimStiolto Respimat
Boehringer IngelheimTiotropium + Olodaterol
AstraZenecaFormoterol
AstraZenecaFormoterol
AstraZenecaFormoterol
AstraZenecaFormoterol
NovartisQVA149
AstraZenecaFormoterol

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 28,139 patients across 50 trials

Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.

Start: Oct 2024Est. completion: Sep 20251,000 patients
Phase 4Completed

IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US

Start: Jan 2024Est. completion: Dec 20250
Phase 4Withdrawn

ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study

Start: Mar 2021Est. completion: Sep 20250
Phase 4Withdrawn
NCT04231214Boehringer IngelheimOlodaterol-Tiotropium

Effects of Spiolto® Respimat® (Tiotropium/Olodaterol) on Cardiac Function in Hyperinflated COPD Subjects

Start: Jan 2020Est. completion: Apr 202332 patients
Phase 4Completed

To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease

Start: Dec 2017Est. completion: Dec 20180
Phase 4Withdrawn

The Effect of Twice Daily vs. Once Daily Bronchodilation on Hyperinflation in COPD Patients During 24 Hours.

Start: Jul 2017Est. completion: Dec 202049 patients
Phase 4Unknown
NCT03152149Boehringer IngelheimTiotropium & olodaterol

INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol

Start: Jun 2017Est. completion: Nov 201980 patients
Phase 4Completed

The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease

Start: Mar 2017Est. completion: Aug 201814 patients
Phase 4Completed
NCT03425617Boehringer IngelheimTiotropium + Olodaterol

Effects of Dual Bronchodilator Treatment on Cardiopulmonary Interactions in COPD

Start: Jan 2017Est. completion: Jun 201825 patients
Phase 4Completed

Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial

Start: Dec 2016Est. completion: Jul 2019158 patients
Phase 4Completed

Effect of Aclidinium/Formoterol on Nighttime Lung Function and Morning Symptoms in Chronic Obstructive Pulmonary Disease

Start: Oct 2015Est. completion: Aug 201840 patients
Phase 4Completed

Phase IV O2 Consumption Study in COPD Patients.

Start: Aug 2015Est. completion: Aug 201651 patients
Phase 4Completed

Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients

Start: Apr 2015Est. completion: Jul 2016267 patients
Phase 4Completed

Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients

Start: Apr 2014Est. completion: Jan 201588 patients
Phase 4Completed

Effect of Symbicort ® on GR in Sputum in COPD

Start: Jan 2013Est. completion: Apr 201531 patients
Phase 4Completed
NCT01715493Eisailysozyme 90 mg

Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom

Start: Oct 2012Est. completion: Jan 201448 patients
Phase 4Completed
NCT01253473AstraZenecaBudesonide/formoterol

Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)

Start: Apr 2012Est. completion: Jan 201646 patients
Phase 4Completed
NCT01760304AstraZenecaBudesonide/formoterol

Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo

Start: Jan 2012Est. completion: Oct 20125 patients
Phase 4Terminated

Tiotropium In Early Chronic Obstructive Pulmonary Disease Patients in China

Start: Nov 2011Est. completion: Aug 2016841 patients
Phase 4Completed

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)

Start: Sep 2011Est. completion: Jan 20162,354 patients
Phase 4Completed
NCT01415518AstraZenecaBudesonide/formoterol

Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients

Start: Sep 2011Est. completion: Dec 2012581 patients
Phase 4Completed
NCT01397890AstraZenecaBudesonide/formoterol

Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)

Start: Jul 2011Est. completion: Jun 2013793 patients
Phase 4Completed

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)

Start: May 2011Est. completion: May 20141,945 patients
Phase 4Completed
NCT01329276AstraZenecaSymbicort® forte Turbohaler®

Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients.

Start: Jun 2010Est. completion: Jan 201110 patients
Phase 4Completed
NCT00939341AstraZenecaBudesonide/formoterol

Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia

Start: Jul 2009Est. completion: Aug 2010862 patients
Phase 4Completed

Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans

Start: Jun 2008Est. completion: Sep 2009311 patients
Phase 4Completed
NCT00489853AstraZenecaBudesonide/formoterol

Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD

Start: Jul 2007Est. completion: Aug 2008137 patients
Phase 4Completed
NCT00496470AstraZenecaBudesonide/formoterol

Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.

Start: May 2007Est. completion: Jun 2008660 patients
Phase 4Completed

Change of Inspiratory Peak Flow in COPD

Start: Apr 2007Est. completion: Oct 200740 patients
Phase 4Completed
NCT00463866AstraZenecaBudesonide/formoterol

Local Phase 4 Pan-European SMART Study

Start: Mar 2007Est. completion: Dec 20088,424 patients
Phase 4Completed

Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation

Start: Oct 2006Est. completion: Aug 200836 patients
Phase 4Completed
NCT00379028AstraZenecaBudesonide/formoterol

Airway Clearance Study

Start: Sep 2006Est. completion: Jul 200754 patients
Phase 4Completed
NCT00316992TakedaRamelteon and Placebo

Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease

Start: Apr 2006Est. completion: Nov 200625 patients
Phase 4Completed

Effects of Tiotropium on Walking Capacity in Patients With COPD

Start: Apr 2005Est. completion: Aug 201033 patients
Phase 4Completed
NCT00242411AstraZenecaBudesonide/formoterol

MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults

Start: Sep 2004Est. completion: Oct 20061,900 patients
Phase 4Completed
NCT00272753AstraZenecaBudesonide/formoterol

Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations

Start: Apr 2004Est. completion: Nov 200520 patients
Phase 4Completed

Effect of Tiotropium on Inflammation and Exacerbations in COPD

Start: Oct 2002Est. completion: Jan 2005220 patients
Phase 4Completed
NCT00691951AstraZenecaBudesonide/formoterol

Effects of Budesonide & Budesonide/Formoterol on Smoking Asthmatic Subjects

Phase 3Completed
NCT07147946Chia Tai TianQing Pharmaceutical GroupTQC3721 Suspension for inhalation

Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Start: Sep 2025Est. completion: Jun 2027
Phase 3Not Yet Recruiting
NCT06473779AstraZenecaBudesonide/formoterol

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

Start: Sep 2024Est. completion: Jun 2027326 patients
Phase 3Active Not Recruiting
NCT06067828AstraZenecaTreatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

Start: Oct 2023Est. completion: Jan 2026171 patients
Phase 3Completed

A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)

Start: Feb 2023Est. completion: Nov 2024374 patients
Phase 3Completed

A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)

Start: Jan 2022Est. completion: Feb 2025645 patients
Phase 3Completed
NCT04751487SanofiItepekimab SAR440340

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

Start: Feb 2021Est. completion: Aug 20251,239 patients
Phase 3Completed

Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection

Start: Jan 2021Est. completion: Dec 20210
Phase 3Withdrawn
NCT04701983SanofiItepekimab SAR440340

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

Start: Dec 2020Est. completion: Aug 20251,127 patients
Phase 3Completed

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

Start: Sep 2020Est. completion: Dec 2022763 patients
Phase 3Completed

A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

Start: Sep 2020Est. completion: Jul 2022790 patients
Phase 3Completed
NCT03256695TevaAlbuterol sulfate

Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Start: Sep 2017Est. completion: Apr 2018405 patients
Phase 3Completed

Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Start: May 2017Est. completion: May 20181,119 patients
Phase 3Completed

Related Jobs in Respiratory

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

12 late-stage (Phase 3) programs — potential near-term approvals
30 companies competing in this space